Patents Examined by Jason Sims
-
Patent number: 9616134Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.Type: GrantFiled: April 25, 2014Date of Patent: April 11, 2017Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Martin Folger, Stefan Lehner
-
Patent number: 9617265Abstract: Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water.Type: GrantFiled: May 23, 2015Date of Patent: April 11, 2017Assignee: DEMERX, INC.Inventors: Richard D. Gless, Jr., William C. Schinzer
-
Patent number: 9604987Abstract: The present invention relates to a composition comprising compound of formula CB6 or CB8, the pharmaceutically-acceptable carrier, solvent, the salts thereof or a combination thereof which is used to treat autophagy-associated diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. The present invention also relates to a method of treating these diseases by administering a therapeutically-effective amount of the compound to the subject in need of the treatment. The present invention further relates to the use of this compound in preparation of the composition to treat the diseases.Type: GrantFiled: October 30, 2015Date of Patent: March 28, 2017Assignee: Hong Kong Baptist UniversityInventors: Min Li, Liang Feng Liu, Ju Xian Song, Hong Jie Zhang
-
Patent number: 9593099Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.Type: GrantFiled: January 13, 2016Date of Patent: March 14, 2017Assignee: Array BioPharma, Inc.Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
-
Patent number: 9593100Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.Type: GrantFiled: January 13, 2016Date of Patent: March 14, 2017Assignee: Array BioPharma, Inc.Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
-
Patent number: 9592227Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: March 13, 2014Date of Patent: March 14, 2017Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger
-
Patent number: 9594011Abstract: Physical property determination of a particle or classification of the particle as a function of the physical property by evaluating scattered light profile from a single particle is disclosed. The particle may include chemical structures that vibrate as a function of a physical property of the particle. The physical property may include an absorptive property of the particle or a chemical composition. From a detected scattered light spectrum, at least two anomalous dispersive regions may be identified. The physical property of the particle may be determined as a function of the at least two regions. A system employing the physical property determination can achieve sensitivities useful for low particle density applications such as detection for biological and chemical agents.Type: GrantFiled: May 21, 2008Date of Patent: March 14, 2017Assignee: Massachusetts Institute of TechnologyInventor: William D. Herzog
-
Patent number: 9582639Abstract: Mobile telecommunications or personal computing apparatus may be specially programmed for predicting whether an unknown biological specimen of an individual to be identified originates from or is related to a member of a particular family. The apparatus may comprise an input device including a barcode reader and a virtual touch screen keyboard whereby DNA profile or mass spectrometry test data may be entered among other data for an individual to be identified, for example, a missing person, victim, crime perpetrator or other unknown individual in hypothetical relationship to another individual or to a family pedigree of typed family members. The typed family pedigree in relation to the individual to be identified in hypothetical relation may be displayed on an output display of the apparatus including at least two different profile typing indicators for each displayed member of the pedigree.Type: GrantFiled: November 21, 2012Date of Patent: February 28, 2017Assignee: University of Tennessee Research FoundationInventors: J. Douglas Birdwell, Carl G. Sapp, N. Quentin Haas, Scott Hansen, Timothy R. Wentz
-
Patent number: 9579418Abstract: The present invention refers to a composition that is useful as a filler for the correction of soft tissue volume loss, for example for the cosmetic treatment of wrinkles, or for the treatment of disorders such as lipoatrophy or lipodystrophy in general, said composition comprising agarose and hyaluronic acid, or a pharmaceutically acceptable salt thereof. The particular interaction that takes place between the two components makes even high concentrations of agarose injectable and tolerable, said high concentrations being particularly useful for ensuring the duration and stability over time of the aesthetic results that are achievable using this filler.Type: GrantFiled: March 31, 2014Date of Patent: February 28, 2017Assignee: ADVANCED AESTHETIC TECHNOLOGIES, INC.Inventor: Mauro Matteuzzi
-
Patent number: 9574238Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myeloma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.Type: GrantFiled: May 22, 2013Date of Patent: February 21, 2017Assignee: Board of Trustees of the University of ArkansasInventors: John D. Shaughnessy, Jr., Bart Barlogie, Fenghuang Zhan
-
Patent number: 9563746Abstract: A method and system of physically solving the charge, mass, and current density functions of organic molecules using Maxwell's equations and computing and rendering the physical nature of the chemical bond using the solutions. The solutions can be used to solve the dipole moments in molecules or induced dipole moments between species that in turn can be used to solve condensed matter parameters and reaction kinetics. The results can be displayed on visual or graphical media. The display can be static or dynamic such that electron motion and specie's vibrational, rotational, and translational motion can be displayed in an embodiment. The displayed information is useful to anticipate reactivity and physical properties. The insight into the nature of the chemical bond of at least one species can permit the solution and display of those of other species to provide utility to anticipate their reactivity and physical properties.Type: GrantFiled: September 25, 2009Date of Patent: February 7, 2017Assignee: BRILLIANT LIGHT POWER, INC.Inventor: Randell L. Mills
-
Patent number: 9549677Abstract: Methods for detecting a seizure, by use of a wavelet transform maximum modulus (WTMM) algorithm applied to body data. A non-transitive, computer-readable storage device for storing data that when executed by a processor, perform such a method.Type: GrantFiled: July 20, 2012Date of Patent: January 24, 2017Assignee: FLINT HILLS SCIENTIFIC, L.L.C.Inventors: Ivan Osorio, Alexey Lyubushin, Didier Sornette
-
Patent number: 9524369Abstract: The present invention is directed to logic for analysis of nucleic acid sequence data that employs algorithms that lead to a substantial improvement in sequence accuracy and that can be used to phase sequence variations, e.g., in connection with the use of the long fragment read (LFR) process.Type: GrantFiled: April 13, 2012Date of Patent: December 20, 2016Assignee: Complete Genomics, Inc.Inventors: Radoje Drmanac, Brock A. Peters, Bahram Ghaffarzadeh Kermani
-
Patent number: 9522892Abstract: Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds.Type: GrantFiled: November 29, 2012Date of Patent: December 20, 2016Assignee: PEROSPHERE INC.Inventors: Solomon S. Steiner, Bryan E. Laulicht, Sasha H. Bakhru, Edith Mathiowitz
-
Patent number: 9514272Abstract: Various short reads can be grouped and identified as coming from a same long DNA fragment (e.g., by using wells with a relatively low-concentration of DNA). A histogram of the genomic coverage of a group of short reads can provide the edges of the corresponding long fragment (pulse). The knowledge of these pulses can provide an ability to determine the haploid genome and to identify structural variations.Type: GrantFiled: October 11, 2012Date of Patent: December 6, 2016Assignee: Complete Genomics, Inc.Inventors: Bahram Ghaffarzadeh Kermani, Radoje Drmanac, Oleg Alferov
-
Patent number: 9506926Abstract: Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated with transcriptional and proteomic subtypes and produced responses that were associated with recurrent genome copy number abnormalities. These associations can now be incorporated into clinical trials that test subtype markers and clinical responses simultaneously.Type: GrantFiled: February 21, 2012Date of Patent: November 29, 2016Assignee: The Regents of the University of CaliforniaInventors: Paul T. Spellman, Joe W. Gray, Anguraj Sadanandam, Laura M. Heiser, William J. Gibb, Wen-lin Kuo, Nicholas J. Wang
-
Patent number: 9474762Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).Type: GrantFiled: May 19, 2015Date of Patent: October 25, 2016Assignee: NOVARTIS AGInventors: Chao Chen, Haibing Deng, Haibing Guo, Feng He, Lei Jiang, Fang Liang, Yuan Mi, Huixin Wan, Yao-Chang Xu, Hongping Yu, Ji Yue Zhang
-
Patent number: 9464978Abstract: The present invention provides methods and systems to combine the capabilities of a hematology analyzer with those of a flow cytometer to yield a far more powerful analytical system than either device alone. In one embodiment, a method of analyzing a cell sample includes receiving a first data generated by an analysis of a first aliquot of the sample on a first particle analyzer having a fluorescence measurement device such as a flow cytometer, detecting at least one unresolved cell population in the first data, and accessing a second data stored on a storage device wherein the second data was previously generated by interrogating a second aliquot of the sample using at least one of a cell volume measurement device and a cell conductivity measurement device in a second particle analyzer such as a hematology analyzer. The unresolved cell population in the first data is then resolved using the second data. Corresponding system embodiments are also disclosed.Type: GrantFiled: March 4, 2009Date of Patent: October 11, 2016Assignee: Beckman Coulter, Inc.Inventors: William H. Gutierrez, Cheng Qian, John S. Riley
-
Patent number: 9447028Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor ? (RAR?) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR?, and in the treatment of diseases and conditions that are mediated by RAR?, that are ameliorated by the activation of RAR?, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.Type: GrantFiled: October 9, 2015Date of Patent: September 20, 2016Assignee: King's College LondonInventors: Jonathan Patrick Thomas Corcoran, Sarkis Barret Kalindjian, Alan David Borthwick, David Reginald Adams, Jane Theresa Brown, David Michel Adrien Taddei, Jason John Shiers
-
Patent number: 9439885Abstract: The present invention is directed to a method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with at least one diglyceride antimicrobial agent.Type: GrantFiled: April 24, 2009Date of Patent: September 13, 2016Assignee: Mead Johnson Nutrition CompanyInventor: Bryon W. Petschow